Allison Lipitz-Snyderman , PhD

Associate Member
Epidemiology & Biostatistics
Directory
Epidemiology
Biostatistics
Health Outcomes
Computational Oncology
Administrative Resources
Career Opportunities
Educational Opportunities
Departmental Newsletter

Allison Lipitz-Snyderman , PhD

Associate Member
Share
Share
Allison Lipitz-Snyderman

Office Phone

646-888-8215

Email

[email protected]

Education

Johns Hopkins University

Dr. Allison Lipitz-Snyderman is a health services researcher in the Department of Epidemiology and Biostatistics at Memorial Sloan Kettering Cancer Center. Her research focuses on: 1) measuring and addressing the quality and safety of cancer care delivery; 2) evaluating the impact of new initiatives, including digital technologies, on clinical and utilization outcomes; and 3) assessing disparities in clinical trial enrollment. She also works with the MSK DigITs (Digital Informatics & Technology Solutions) team, providing methodological support for value and outcomes assessments of healthcare technology initiatives. She has expertise directing studies using data sources such as large-scale national claims, cancer registries, and electronic medical records. She also serves as Co-Chair of the MSK Cancer Alliance Cancer Control and Population Sciences Sub-committee. Her research has been supported by the National Cancer Institute, the National Comprehensive Cancer Network, the National Institute for Healthcare Management Foundation, and AARP/NQF/OptumLabs, among others.

Publications

Selected peer-reviewed publications:

  1. Lipitz-Snyderman A, Steinwachs D, Needham DM, Colantuoni E, Morlock LL, Pronovost PJ. Impact of a statewide intensive care unit quality improvement initiative on hospital mortality and length of stay: retrospective comparative analysis. BMJ. 2011 Jan 28;342:d219. PMCID: 3031651.
  2. Lipitz-Snyderman A, Sima CS, Atoria CL, Elkin EB, Anderson C, Blinder V, Tsai CJ, Panageas KS, Bach PB. Physician-Driven Variation in Nonrecommended Services Among Older Adults Diagnosed With Cancer. JAMA Intern Med. 2016 Oct 1;176(10):1541-1548. PMCID: PMC5363077.
  3. Lipitz-Snyderman A, Korenstein D. Reducing Overuse-Is Patient Safety the Answer? [invited editorial] JAMA. 2017 Feb 28;317(8):810-811.
  4. Lipitz-Snyderman A, Pfister D, Classen DC, Killen AK, Atoria CL, Epstein A, Anderson C, Fortier E, & Weingart S. Preventable adverse events in cancer care: Measuring risk and harm across the continuum. Cancer. 2017 Dec 1;123(23):4728-4736. doi: 10.1002/cncr.30916.
  5. Lipitz-Snyderman A, Kale M, Robbins L, Pfister D, Fortier E, Pocus V, Chimonas S, Weingart SN. Peers without fears? Barriers to effective communication among primary care physicians and oncologists about diagnostic delays in cancer. BMJ quality & safety. 2017. doi: 10.1136/bmjqs-2016-006181. PubMed PMID: 28655713.

View a full listing of Allison Lipitz-Snyderman ’s journal articles.

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Allison Lipitz-Snyderman discloses the following relationships and financial interests:

No disclosures meeting criteria for time period


The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].


View all disclosures